May 19 is the second annual Viral Hepatitis Testing Day, an opportunity to raise awareness among healthcare providers and the public about screening for chronic hepatitis B and C. According to the Centers for Disease Control and Prevention (CDC), an estimated 75% of people with hepatitis C virus (HCV) are not aware they are infected.
HIVandHepatitis.com coverage of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) in Amsterdam, April 24-28, 2013.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, and prevention and treatment of hepatocellular carcinoma.
For people with chronic hepatitis C who cannot wait for all-oral regimens, interferon-based therapy is still a reality. Researchers at the recent EASL International Liver Congress (EASL 2013) presented promising data showing that several experimental direct-acting antiviral agents (DAAs) can significantly improve response rates without reducing tolerability.
HIVandHepatitis.com coverage of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), March 3-6, 2013, in Atlanta.
Conference highlights include experimental therapies for HIV and hepatitis C, HIV cure research, aging, HIV-related conditions and treatment complications, HIV treatment as prevention and PrEP, and HIV/HBV and HIV/HCV coinfection.